Eli Lilly (LLY) Other Non-Current Assets (2009 - 2026)

Eli Lilly has reported Other Non-Current Assets for 18 years, with the latest figure at $7.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 19.03% year-over-year to $7.2 billion; the trailing twelve-month figure through Mar 2026 stood at $7.2 billion (up 19.03% YoY), and the FY2025 full-year result was $7.0 billion, up 22.24% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $7.2 billion, up from $7.0 billion in the prior quarter.
• The five-year high for Other Non-Current Assets was $7.2 billion in Q1 2026, with the low at $4.3 billion in Q1 2022.
• Historically, Other Non-Current Assets has averaged $5.3 billion across 5 years, with a median of $4.9 billion in 2023.
• Annual changes were most pronounced in 2024 — Other Non-Current Assets gained 4.27% — and 2025, when it rose 29.03%.
• Eli Lilly's Other Non-Current Assets stood at $4.3 billion in 2022, then gained by 15.05% to $5.0 billion in 2023, then increased by 14.63% to $5.7 billion in 2024, then gained by 22.24% to $7.0 billion in 2025, then increased by 3.42% to $7.2 billion in 2026.
• The last three Other Non-Current Assets figures came in at $7.2 billion (Q1 2026), $7.0 billion (Q4 2025), and $6.4 billion (Q3 2025), per Business Quant data.